Related Experiment Video

Updated: May 26, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

The Akt signaling pathway: an emerging therapeutic target in malignant melanoma

SubbaRao V Madhunapantula1, Paul J Mosca, Gavin P Robertson

  • 1College of Medicine, Pennsylvania State University, Hershey, PA, USA.

Cancer Biology & Therapy
|December 14, 2011
PubMed

Insights

Targeting the PI3K-Akt3 pathway shows promise for melanoma treatment. Further research is needed to optimize therapies, identify new targets, and improve drug delivery for better patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Deregulated PI3K-Akt3 pathway activity is observed in approximately 70% of melanomas.
  • Preclinical studies show Akt3 and PRAS40 targeting inhibits melanoma development in mice.
  • Early clinical trials highlight the need for improved therapeutic strategies.

Purpose of the Study:

  • To review key targets within the PI3K-Akt3 signaling pathway in melanoma.
  • To discuss the current status of pharmacological agents targeting this pathway.
  • To explore strategies for enhancing the efficacy of melanoma therapeutics.

Main Methods:

  • Review of preclinical and clinical studies on PI3K-Akt3 pathway inhibitors in melanoma.
  • Analysis of existing and investigational pharmacological agents.
  • Discussion of patient selection, drug optimization, and delivery strategies.

Main Results:

  • The PI3K-Akt3 pathway is a significant target in melanoma, with preclinical success.
  • Clinical trials indicate a need for patient stratification based on pathway deregulation.
  • Optimization of potency, toxicity, and delivery of targeted agents is crucial.

Conclusions:

  • Targeting the PI3K-Akt3 pathway holds therapeutic potential for melanoma.
  • Further research should focus on personalized medicine approaches and combination therapies.
  • Developing more effective and safer drugs is essential for clinical success.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...